Your browser doesn't support javascript.
loading
Bilateral Wilms tumor with anaplasia: A report from the Children's Oncology Group Study AREN0534.
Romao, Rodrigo L P; Aldrink, Jennifer H; Renfro, Lindsay A; Mullen, Elizabeth A; Murphy, Andrew J; Brzezinski, Jack; Malek, Marcus M; Benedetti, Daniel J; Cost, Nicholas G; Smith, Ethan; Dome, Jeffrey S; Davidoff, Andrew M; Treece, Amy; Parsons, Lauren N; Fernandez, Conrad V; Tornwall, Brett; Shamberger, Robert C; Paulino, Arnold; Kalapurakal, John A; Geller, James I; Ehrlich, Peter F.
Afiliación
  • Romao RLP; Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
  • Aldrink JH; Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio, USA.
  • Renfro LA; Division of Biostatistics, University of Southern California and Children's Oncology Group, Los Angeles, California, USA.
  • Mullen EA; Boston Children's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA.
  • Murphy AJ; St Jude's Children's Research Hospital, Memphis, Tennessee, USA.
  • Brzezinski J; Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
  • Malek MM; Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Benedetti DJ; Monroe Carell Jr Children's Hospital at Vanderbilt, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Cost NG; The Surgical Oncology Program at the Children's Hospital of Colorado, University of Colorado, Denver, Colorado, USA.
  • Smith E; Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Dome JS; Children National Hospital, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
  • Davidoff AM; St Jude's Children's Research Hospital, Memphis, Tennessee, USA.
  • Treece A; Children's Hospital of Alabama, Birmingham, Alabama, USA.
  • Parsons LN; Children's Hospital of Wisconsin, Milwaukee, Wisconsin, USA.
  • Fernandez CV; IWK Health, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Tornwall B; Department of Biostatistics, University of Florida, Gainesville, Florida, USA.
  • Shamberger RC; Boston Children's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA.
  • Paulino A; MD Anderson Cancer Center Houston, Houston, Texas, USA.
  • Kalapurakal JA; Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, USA.
  • Geller JI; Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Ehrlich PF; Section of Pediatric Surgery, C.S. Mott Children's Hospital University of Michigan, Ann Arbor, Michigan, USA.
Pediatr Blood Cancer ; 71(7): e30981, 2024 Jul.
Article en En | MEDLINE | ID: mdl-38637871
ABSTRACT

INTRODUCTION:

The purpose of this study is to examine the outcomes in children with anaplastic bilateral Wilms tumor (BWT) from study AREN0534 in order to define potential prognostic factors and areas to target in future clinical trials.

METHODS:

Demographic and clinical data from AREN0534 study patients with anaplasia (focal anaplasia [FA], or diffuse anaplasia [DA]) were compared. Event-free survival (EFS) and overall survival (OS) were reported using Kaplan-Meier estimation with 95% confidence bands, and differences in outcomes between FA and DA compared using log-rank tests. The impact of margin status was analyzed.

RESULTS:

Twenty-seven children who enrolled on AREN0534 had evidence of anaplasia (17 DA, 10 FA) in at least one kidney and were included in this analysis. Twenty-six (96%) had BWT. Nineteen percent had anaplastic histology in both kidneys (four of 17 DA, and one of 10 FA). Forty-six percent with BWT had bilateral nephron-sparing surgery (NSS); one child who went off protocol therapy, eventually required bilateral completion nephrectomies. Median follow-up for EFS and OS was 8.6 and 8.7 years from enrollment. Four- and 8-year EFS was 53% [95% confidence interval (CI) 34%-83%] for DA; 4-year EFS was 80% [95% CI 59%-100%], and 8-year EFS 70% [95% CI 47%-100%] for FA. Three out of 10 children with FA and eight out of 17 children with DA had events. EFS did not differ statistically by margin status (p = .79; HR = 0.88). Among the six children who died (five DA, one FA), all experienced prior relapse or progression within 18 months.

CONCLUSION:

Events in children with DA/FA in the setting of BWT occurred early. Caution should be taken about interpreting the impact of margin status outcomes in the context of contemporary multimodal therapy. Future targeted investigations in children with BWT and DA/FA are needed.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tumor de Wilms / Neoplasias Renales Límite: Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tumor de Wilms / Neoplasias Renales Límite: Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Canadá